Scroll to top

Scroll to top

Investors

About

Stock Quote

NASDAQIMUX

Fast Facts

Company Founded in 2016
Experts in Selective Oral Drugs in Immunology
Differentiated Development Programs
Headquartered in New York City
NASDAQ: IMUX

Latest News

November 26, 2024

Immunic, Inc. to Participate in Investor Conference in December

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...

November 13, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company...

November 7, 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials...

View All

Immunic Therapeutics
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Rx Communications
Paula Schwartz
Managing Director
+1 917 322 2216
immunic@rxir.com